申请人:Taisho Pharmaceutical Co., Ltd.
公开号:US05116995A1
公开(公告)日:1992-05-26
Carbazole compounds represented by the formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, R.sup.2 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkanoyl group having 2 to 6 carbon atoms or a benzoyl group, R.sup.3 and R.sup.4 are the same or different, and are each hydrogen atom, an alkyl group having 1 to 7 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkyl group having 1 to 3 carbon atoms substituted by a phenyl group, or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are attached form a morpholino group, a piperidino group, a pyrrolidino group or a piperazino group, and n is an integer from 1 to 3, and salts thereof have strong antipsychotic activity.
该文献描述了由以下式子表示的Carbazole化合物:##STR1##其中R.sup.1是氢原子或有1至5个碳原子的烷基,R.sup.2是氢原子,有1至5个碳原子的烷基,有2至6个碳原子的烷酰基或苯甲酰基,R.sup.3和R.sup.4相同或不同,均为氢原子,有1至7个碳原子的烷基,有2至4个碳原子的烯基,有1至3个碳原子的烷基,其上取代了苯基,或R.sup.3和R.sup.4与它们所连接的氮原子一起形成吗啡环基、哌啶环基、吡咯烷环基或哌嗪环基,n为1至3的整数,以及它们的盐具有强烈的抗精神病活性。